Patrys secures 50% revenue sharing agreement

• Patrys entered a binding revenue sharing agreement with Yale University for its deoxymab intellectual property portfolio.
• Following the announcement, the company's share price remained unchanged at $0.040.
• The agreement is designed to preserve long-term shareholder exposure while reducing future capital requirements.

Patrys (ASX:PAB) executed a binding agreement with Yale University to secure a 50% share of all future commercialisation revenue from its deoxymab intellectual property portfolio.

The transaction marks a structural transition towards an academic research framework compared to traditional internal development models.

"This transaction represents an important strategic milestone for Patrys and the deoxymab platform," said Patrys CEO Dr Samantha South.

The company stated that the transaction structure includes cash and non-cash considerations such as equity interests, licensing revenue, royalties, and milestone payments.

Following the announcement, the Patrys share price was unchanged at $0.040.

The new structure facilitates advancing the portfolio alongside a potential new Yale venture named Nucleicon founded by inventor Dr James Hansen.

The ongoing commercialisation strategy aims to leverage external specialist expertise and academic research capabilities to lower direct corporate funding obligations.